Information Provided By:
Fly News Breaks for October 8, 2019
STSA
Oct 8, 2019 | 08:36 EDT
Credit Suisse analyst Evan Seigerman started coverage of Satsuma Pharmaceuticals with an Outperform rating and a $16 price target. The analyst is positive on Satsuma as he believes the path to regulatory approval is de-risked, the drug/device is differentiated, and sees upside in commercialization with a large addressable market that could support multiple competitors.
News For STSA From the Last 2 Days
There are no results for your query STSA